Joseph Driscoll insider trades: Akoya Biosciences (AKYA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Joseph reports to the SEC
Open-market buys and sales
16 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 14, 2022 | AKYA | ↓ Sell | 24,613 | $12.54 | $309K | Direct | Dec 16, 2022 (2d) |
| Jan 15, 2019 | QTRX | ↓ Sell10b5-1 | 15,000 | $20.51 | $308K | Direct | Jan 15, 2019 (0d) |
| Dec 13, 2018 | QTRX | ↓ Sell | 20,000 | $19.21 | $384K | Direct | Dec 14, 2018 (1d) |
| Dec 3, 2018 | QTRX | ↓ Sell | 20,000 | $18.47 | $369K | Direct | Dec 6, 2018 (3d) |
| Nov 28, 2018 | QTRX | ↓ Sell | 20,000 | $17.80 | $356K | Direct | Nov 30, 2018 (2d) |
| Nov 15, 2018 | QTRX | ↓ Sell | 25,000 | $16.60 | $415K | Direct | Nov 16, 2018 (1d) |
| Nov 8, 2018 | QTRX | ↓ Sell | 2,337 | $17.36 | $41K | Direct | Nov 13, 2018 (5d) |
| Aug 1, 2016 | PCCC | ↓ Sell | 3,377 | $25.77 | $87K | Direct | Aug 3, 2016 (2d) |
| Feb 9, 2016 | PCCC | ↓ Sell | 4,725 | $22.19 | $105K | Direct | Feb 10, 2016 (1d) |
| Nov 6, 2015 | PCCC | ↓ Sell | 3,375 | $22.31 | $75K | Direct | Nov 10, 2015 (4d) |
| May 7, 2015 | PCCC | ↓ Sell | 3,372 | $24.40 | $82K | Direct | May 8, 2015 (1d) |
| Feb 10, 2015 | PCCC | ↓ Sell | 4,047 | $23.79 | $96K | Direct | Feb 11, 2015 (1d) |
| May 6, 2014 | PCCC | ↓ Sell | 3,370 | $20.23 | $68K | Direct | May 8, 2014 (2d) |
| Dec 12, 2011 | SUMR | ↓ Sell | 13,328 | $7.14 | $95K | Direct | Dec 13, 2011 (1d) |
| May 16, 2011 | SUMR | ↓ Sell | 10,000 | $9.10 | $91K | Direct | May 18, 2011 (2d) |
| Dec 9, 2010 | SUMR | ↓ Sell | 10,000 | $7.37 | $74K | Direct | Dec 10, 2010 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Joseph Driscoll's insider trades
Joseph Driscoll is Chief Financial Officer at Akoya Biosciences (AKYA). Since Dec 9, 2010, Joseph has reported no open-market purchases and 16 sales worth $3.0M on SEC Form 4. There have been no open-market trades in the last 12 months.
1 sale (10% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include option exercises (15 filings), grants and awards (13 filings), shares withheld for taxes (7 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AKYA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.